Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-02
2000-01-04
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544 63, 544116, 544237, 5142305, 5142325, 5142338, A61K 3150, A61K 31535, C07D23730, C07D26502
Patent
active
060110368
ABSTRACT:
The present invention relates to novel antidiabetic compounds, their tautomeric forms, their analogues, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione compounds of the general formula (I), and their analogues, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##
REFERENCES:
patent: 4873255 (1989-10-01), Yoshioka
patent: 5002953 (1991-03-01), Hindley
patent: 5037842 (1991-08-01), Goldstein
patent: 5468762 (1995-11-01), Malamas
patent: 5478851 (1995-12-01), Cantello
patent: 5478852 (1995-12-01), Olefsky
patent: 5478853 (1995-12-01), Regnier
patent: 5521201 (1996-05-01), Hindley
Bernard et al., "A New and Efficient Synthesis of Phthalazin-1(2H)-ones," Synthesis, vol. 3, pp. 317-320, Mar. 1998.
Messier, C. et al., Behavioral Brain Research, 75 (1966) 1-11.
Sohda, T. et al., Chem Pharm Bull. 30, 10 (1982), 3580-3600.
Clark, et al. J. Med. Chem 34 (1991) 319-325.
Dow, R. L. et al., J. Med. Chem 34 (1991) 1538-1544.
Hulin, et al., J. Med. Chem 35 (1992) 1853-1864.
Sohda, T. et al., J. Med. Chem 35 (1992) 2617-2626.
Goldsein, et al., J. Med. Chem. 36 (1993) 2238-2240.
Cantello, et al., J. Med. Chem 37 (1994) 3977-3985.
English Translation of JP-A-0912575.
M. Modan, et al., J. Clin. Invest. (1985) vol. 75, pp. 809-817.
O. G. Kolterman, et al., J. Clin. Invest. (1981) vol. 68, pp. 957-969.
E. Ferrannini, et al., The New England Journal of Medicine (1987) vol. 317, pp. 350-357.
D.C. Shen, et al., J. Clin. Endocrinol. Metab. (1988) vol. 66, pp. 580-583.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, pp. 1496-1497.
Clifford Bailey, "Potential New Treatments for Type 2 Diabetes", Chemistry & Industry, Jan. 19, 1998, pp. 53-57.
t. Antonucci et al., "Imparied Glucose Tolerance is Normalized by Treatment with the Thiazolidinedione Troglitazone" Diabetes Care, vol. 20, No. 2, Feb. 1997, pp. 188-193.
Cantello, Barrie C. C., et al. "Omega (Heterocyclylamino)alkoxy[benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents." Journal of Medical Chemistry, vol. 37, No. 23 (1994) pp. 3977-3985.
Chakrabarti Ranjan
Gurram Ranga Madhavan
Lohray Braj Bhushan
Lohray Vidya Bhushan
Ramanujam Rajagopalan
Dr. Reddy's Research Foundation
Kessinger Ann M.
Reddy-Cheminor Inc.
Shah Mukund J.
LandOfFree
Heterocyclic compounds having antidiabetic hypolipidemic antihyp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds having antidiabetic hypolipidemic antihyp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds having antidiabetic hypolipidemic antihyp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072837